Why side effects vary so much across "peptide therapy"
The term "peptide therapy" covers an enormous range of compounds, and lumping their side effects together produces more confusion than insight. The most important dividing line is whether the compound is FDA-approved.
An FDA-approved medicine has gone through clinical trials that specifically document side effects at scale — what proportion of people experience nausea, headache, or more serious events, how that compares to placebo, and how those rates change at different doses. That documentation is required for approval and is published in the prescribing information.
An investigational compound has not completed that process. Side effects in humans are either unknown (because human trials have not been done) or known only from small, preliminary studies that lack the statistical power to characterise rare events. The absence of documented side effects is not the same as the absence of side effects — it means the research to find them has not been done.
This guide covers both categories honestly. For approved compounds, the evidence is detailed. For investigational ones, the honest answer is shorter: we do not know yet.
GLP-1 medicines: the well-documented side-effect profile
Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are the most widely used peptide-based drugs today, and their side-effect profiles are among the best documented in modern clinical pharmacology. Large trials with thousands of participants, followed for a year or more, give a clear statistical picture.
The dominant side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These happen because GLP-1 receptor agonists slow gastric emptying — the rate at which the stomach empties into the small intestine. This mechanism is intentional (it reduces appetite and calorie intake), but it takes the gut time to adjust.
In the STEP 1 trial of semaglutide, the majority of gastrointestinal side effects were rated mild to moderate in severity. They were most common in the early weeks of treatment and during dose escalation periods, and they tended to diminish as the body adjusted to the medicine. The pattern in the SURMOUNT-1 trial for tirzepatide was similar. The standard clinical approach is dose titration: starting at the lowest available dose and increasing gradually over several months, giving the gut time to adapt at each step.
Injection-site reactions are also common across all injectable peptides — mild redness, itching, or tenderness at the site of the injection, particularly early in treatment. These are typically minor and tend to improve over time.
| Side effect category | Frequency | When most common | Usually resolves? |
|---|---|---|---|
| Nausea | Common | Early weeks; dose escalation | Often yes, over weeks |
| Vomiting | Common (less than nausea) | Early weeks; dose escalation | Often yes |
| Diarrhea | Common | Variable | Often yes |
| Constipation | Common | Variable | Often yes |
| Injection-site reaction | Common | Early treatment | Usually yes |
| Pancreatitis | Rare | Any time | Requires discontinuation |
| Gallbladder problems | Rare | Any time | Medical evaluation required |
| Thyroid C-cell tumors (animal signal) | Unknown in humans | N/A — rodent data | N/A |
Rare but serious effects — what the FDA prescribing labels say
The common digestive side effects get the most attention because they affect the most people. But the FDA prescribing information for semaglutide and tirzepatide also lists rarer, more serious events that are important to understand.
Pancreatitis — inflammation of the pancreas — has been reported in people taking GLP-1 medicines. The causal relationship is debated, but the signal is real enough that the FDA includes it as a warning. Anyone who experiences severe abdominal pain while on these medicines should contact their clinician promptly.
Gallbladder problems, including gallstones and cholecystitis, appear at higher rates in people taking GLP-1 drugs compared to placebo. The mechanism is likely related to the drug's effect on gastric motility and the composition of bile. This is a known and documented risk, particularly for people with existing risk factors for gallstone disease.
Animal studies — specifically in rodents — showed a signal for a rare form of thyroid cancer (medullary thyroid carcinoma) at high GLP-1 drug exposures. This signal has not been demonstrated in humans, but it is the reason these drugs carry a boxed warning for people with a personal or family history of medullary thyroid cancer or Multiple Endocrine Neoplasia type 2.
These are not reasons to avoid these medicines for appropriate patients — the benefit-risk calculus for the right person, evaluated by a clinician who knows their full history, often strongly favors treatment. But they are real risks that belong in the conversation, not omitted in favor of only discussing the positive effects.
Long-term safety: what the SELECT trial showed
One of the most significant long-term safety datasets for GLP-1 medicines came from the SELECT trial, which followed over 17,000 people with cardiovascular disease and excess weight (but without diabetes) for several years. Half received once-weekly semaglutide; half received a placebo.
The primary finding was a cardiovascular benefit: semaglutide reduced the rate of serious cardiovascular events — heart attacks, strokes, and cardiovascular death — by approximately 20 percent compared with placebo. That is a long-term safety and efficacy signal from a very large trial.
On the safety side, the trial gave a detailed picture of what happens to people on semaglutide over years, not just months. The gastrointestinal side effects seen in shorter trials continued to be the dominant side-effect category. Serious adverse events were tracked carefully across both groups.
The SELECT data add something important to the side-effect conversation: long-term follow-up at scale. For many medicines, rare side effects only become visible when you watch large numbers of people for long periods. This trial provides that visibility for semaglutide in a cardiovascular population. The overall picture that emerged was one where the cardiovascular benefit was substantial and the safety profile, while not free of side effects, was manageable in this population.
Tesamorelin: a known but different side-effect profile
Tesamorelin is a growth-hormone-releasing hormone (GHRH) analogue, approved by the FDA for excess abdominal fat in people with HIV-associated lipodystrophy. Its mechanism is different from GLP-1 drugs — rather than slowing gastric emptying, it stimulates the pituitary to release growth hormone, which then reduces visceral fat.
The side-effect profile reflects that different mechanism. In the pivotal 26-week trial, which compared tesamorelin 2 mg daily to placebo, visceral adipose tissue fell 15.2% in the tesamorelin group versus a 5.0% rise in the placebo group. IGF-1 — a growth factor elevated by higher growth hormone activity — rose 81.0% in the treatment group. That IGF-1 elevation is relevant to the side-effect picture.
A 2011 review of the two pivotal trials found tesamorelin was generally well tolerated. Serious adverse events occurred in fewer than 4% of participants. The characteristic side effects were those you would predict from mildly elevated growth hormone: joint aches and pains (arthralgia), headaches, and mild peripheral edema (fluid retention), particularly in the early weeks of treatment.
The prescribing label notes that tesamorelin is contraindicated in people with active malignancy. This caution relates to the IGF-1 elevation: epidemiological data, including a 2004 systematic review in The Lancet, showed an association between higher circulating IGF-1 and the risk of prostate cancer and premenopausal breast cancer. The causal mechanism is not established, but the contraindication for active malignancy reflects a reasonable precautionary stance given the IGF-1 signal.
Injection-site reactions — redness, pain, and itching at the injection site — are listed as common in the prescribing information. These are typical of subcutaneous injectable medicines and usually manageable.
Investigational peptides: what we honestly do not know
The side-effect discussion becomes much shorter and more honest for investigational compounds. BPC-157, CJC-1295, ipamorelin, epithalon, and many other peptides widely discussed in fitness and biohacking communities are not FDA-approved drugs. The key implication is that their human side-effect profiles are largely unknown.
A 2025 systematic review of BPC-157 in humans found that human evidence was "extremely limited" — only three small pilot studies had been published, none of them completed randomised controlled trials. Without large, well-designed human trials, it is not possible to characterise what proportion of people experience a given side effect, which side effects are rare versus common, or how those rates compare to a control group. The absence of documented side effects is not reassurance — it reflects the absence of the research needed to find them.
Animal studies of these compounds are more extensive, but animal data do not reliably predict human side effects. Many compounds that appeared safe in animal models produced unexpected problems in human trials. Extrapolating from animal studies to human safety is a known scientific limitation, not a workaround.
For compounds like CJC-1295 and ipamorelin, which stimulate growth hormone release similarly to tesamorelin, one might ask whether the tesamorelin side-effect profile gives guidance. It provides a framework — joint aches, headache, edema are plausible effects of growth hormone elevation — but it does not substitute for human trial data on the specific compound. Dose, formulation, half-life, and receptor selectivity all affect the actual profile.
The responsible position is clear: for investigational peptides, the side-effect profile in humans is not established. That does not mean they are definitely dangerous. It means the question is open. Anyone using these compounds outside a clinical trial is doing so without the safety net that the clinical development process is designed to provide.
Retatrutide: an investigational triple agonist with Phase 2 data
Retatrutide occupies an interesting middle position. It is investigational — not FDA-approved — but it has published Phase 2 trial data that give some picture of its side-effect profile in a clinical setting.
In the 2023 Phase 2 obesity trial, participants received doses of 1, 4, 8, or 12 mg once weekly. Gastrointestinal side effects were the dominant adverse events — a pattern consistent with what you would expect from a compound that includes GLP-1 and glucagon receptor agonism. At higher doses, these effects were more pronounced.
But Phase 2 data involve a few hundred participants, followed for less than a year. The larger, longer Phase 3 TRIUMPH program — with over 5,800 participants — is still ongoing. Phase 3 trials exist specifically to characterise what Phase 2 trials cannot: rare events, long-term effects, and the side-effect profile across a broader population. Until that program concludes and the data are reviewed by the FDA, retatrutide's complete side-effect profile is not established. It is investigational.
This distinction matters practically. Someone who has seen the Phase 2 weight-loss data and wants access to retatrutide should understand that no approved version exists. Research-chemical versions are operating entirely outside the clinical and regulatory systems that generated the Phase 2 data.
How dose titration reduces early side effects
For approved GLP-1 drugs, one of the most important tools for managing side effects — particularly the digestive ones — is dose titration. Starting at the lowest available dose and increasing gradually, on a defined schedule of weeks to months, gives the body time to adapt to each level before moving higher.
This is why every FDA-approved GLP-1 drug label specifies a titration schedule. It is not just about reaching the target dose — it is specifically about minimising the side-effect burden along the way. Most of the digestive side effects seen in clinical trials were most intense during early treatment and dose increases, and they tended to ease as adaptation occurred.
The same logic applies — arguably even more so — to investigational compounds. A clinician supervising use of an unapproved compound should be starting low, increasing slowly, and watching carefully for any signal that the compound is not being tolerated. The absence of an approved titration schedule means the clinician has to apply judgment rather than follow a proven protocol, which makes clinical supervision more rather than less important.
Monitoring and PeptidePanel
Managing side effects is an ongoing process, not a one-time checklist. The timing and pattern of side effects — when they started, how severe they have been, whether they are improving or worsening — is exactly the kind of longitudinal information a clinician needs to decide whether to adjust the dose, switch compounds, or investigate further.
For biomarker-relevant side effects — IGF-1 elevation on tesamorelin, blood glucose changes on GLP-1 drugs, kidney function on any injectable — lab results over time are part of that picture. A single reading is less useful than a trend.
PeptidePanel is built to organise that information. It logs the protocol your clinician established, stores your lab results as they come in, and flags when follow-up tests are due. It does not diagnose or recommend — it is the tracking layer that helps you and your clinician see the full picture at a follow-up appointment, without having to reconstruct it from memory or a pile of paper results.